Patient Advocate Says Novartis' $475,000 Breakthrough Should Cost Just $160,000

David Mitchell, 67, says he ’s sure that Novartis’ Kymriah is a breakthrough medicine, and that he will need a similar medicine to treat his own blood cancer. He’s sure of something else, too: Novartis is charging too much.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: NYSE:NVS NASDAQ:CELG NASDAQ:GILD NASDAQ:JUNO Source Type: news

Related Links:

While crowdfunding is helping patients gain access to conventional but costly mainstream treatment, people also use it for treatment at clinics offering alternative medicine.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
(Reuters Health) - Women with breast cancer who get newer genetic tests to estimate their risk of recurrence may not be any more anxious about their test results than their peers who get older tests that focus on fewer genes, a recent study suggests.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Macadamia nuts are a nutritious food with many potential benefits, including lowering the risk of heart disease and possibly helping prevent cancer. Learn more about the benefits of macadamia nuts, as well as some drawbacks to be aware of, here.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Nutrition / Diet Source Type: news
Abstract Tamoxifen (TMX) is the main drug used both in pre and postmenopausal women as adjuvant treatment for hormone receptor-positive breast cancer. An important barrier to the use of TMXis the development ofdrug resistance causedby molecular processes related to genetic and epigenetic mechanisms, such as the actions of cytochrome P450 2D6 (CYP2D6) polymorphisms and of its metabolites. The present study aimed to review recent findings related to the impact of CYP2D6 polymorphisms and how they can affect the results of TMX in breast cancer treatment. The keywords CYP2D6, tamoxifen, and breast cancer were searched in the P...
Source: Revista Brasileira de Ginecologia e Obstetricia - Category: OBGYN Source Type: research
Conclusion The present case highlights one of the less common but more serious consequences of radiotherapy for cervical cancer, which has an increasing incidence in younger women, raising concerns about the long-termconsequences of its management.
Source: Revista Brasileira de Ginecologia e Obstetricia - Category: OBGYN Source Type: research
Good news is always welcome, especially when talking about something as serious as cancer. And there is plenty of welcome information in the American Cancer Society ’s release of our annual report on“Cancer Statistics, 2019” and its accompanying consumer-oriented version of“Cancer Facts&Figures 2019.” Among the good news in this report: A significant […]Find jobs at  Careers by KevinMD.com.  Search thousands of physician, PA, NP, and CRNA jobs now.  Learn more.
Source: Kevin, M.D. - Medical Weblog - Category: General Medicine Authors: Tags: Conditions Oncology/Hematology Source Type: blogs
Lung cancer experts say the recent decision to restrict the use of durvalumab immunotherapy to patients with high PD-L1 expression is'a lost therapeutic opportunity. 'Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
(Reuters Health) - Cancer survivors have higher-than-average rates of medical financial hardship, a U.S. study suggests.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Abstract Background: Chemotherapeutic agents of anthracyclines class and humanized monoclonal antibodies are effective treatments for breast cancer, however, they present a potential risk of cardiotoxicity. Several predictors have been recognized as predictors in the development of cardiac toxicity, and the evaluation of left ventricular segmental wall motion abnormalities (LVSWMA) has not been studied. Objective: To analyze prospectively the role of LVSWMA among echocardiographic parameters in the prediction of development of cardiotoxicity in breast cancer patients undergoing treatment with chemotherapy. Methods: Prospec...
Source: Arquivos Brasileiros de Cardiologia - Category: Cardiology Source Type: research
Abstract Background: Chemotherapeutic agents of anthracyclines class and humanized monoclonal antibodies are effective treatments for breast cancer, however, they present a potential risk of cardiotoxicity. Several predictors have been recognized as predictors in the development of cardiac toxicity, and the evaluation of left ventricular segmental wall motion abnormalities (LVSWMA) has not been studied. Objective: To analyze prospectively the role of LVSWMA among echocardiographic parameters in the prediction of development of cardiotoxicity in breast cancer patients undergoing treatment with chemotherapy. Methods: Prospec...
Source: Arquivos Brasileiros de Cardiologia - Category: Cardiology Source Type: research
More News: Cancer | Cancer & Oncology | Pharmaceuticals